Drug maker Lupin inks licensing pact with Galenicum for injectable Semaglutide

Drug maker Lupin announced a significant partnership. Its subsidiary, Lupin Atlantis Holdings SA, has signed an agreement with Galenicum Health. This collaboration focuses on diabetes and weight management medication, specifically injectable Semaglutide. Galenicum will handle development and manufacturing. Lupin will manage regulatory submissions, approvals, and commercialisation.